Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Research Report 'A Good Gut Feeling' by NDF Research

🕔1/25/2017 10:24:29 AM 2573

NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Update

🕔11/22/2016 8:27:13 AM 2192

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) AGM Presentation

🕔11/15/2016 11:51:40 AM 1951

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/15/2016 11:50:40 AM 2175

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/14/2016 11:17:04 AM 2224

Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives R&D Tax Refund

🕔10/14/2016 8:30:42 AM 1756

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/13/2016 8:25:28 AM 1757

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article

Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'

🕔10/4/2016 8:30:00 AM 1985

Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Submission Major Milestone Achieved

🕔10/4/2016 8:29:45 AM 2400

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Completion of Target Safety Study

🕔9/8/2016 8:27:28 AM 2661

Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.

Read Full Article
###

10,008 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 1479) (Last 30 Days: 2196) (Since Published: 10008) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Social Media